Delivery Order SPE2DR25D3111-SPE2DR26FF3WT
- Not listed
- The Defense Logistics Agency awarded a $5,700.57 firm fixed price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on November 13, 2025, with completion scheduled for November 14, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- On January 7, 2026, the Defense Logistics Agency awarded a $19,635 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes. This non-set-aside contract represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 and extending through December 2026. The vaccine product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with a completion date...
- The Defense Logistics Agency awarded a $3,339.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on December 4, 2025, with completion scheduled for December 5, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves...
- The Defense Logistics Agency awarded a $1,936.91 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on December 12, 2025, with completion expected by December 15, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The vaccine delivery will be performed at the contractor's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,679.97 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML Vial 10ML vaccine supply. This non-competitive delivery order was issued on June 16, 2025, with an ultimate completion date of June 17, 2025, utilizing firm fixed pricing. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the federal government's medical supply chain requirements. This...
- The Defense Logistics Agency awarded a $6,790 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on December 15, 2025, with completion targeted for December 16, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and running through December 2026. The vaccine product will be performed at...
- AmerisourceBergen Drug Corp received a delivery order valued at $47,613.71 from the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a competitively awarded contract with no set-aside designation. The vaccine product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $3,576.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on January 8, 2026, with completion scheduled for January 9, 2026. This is a non-set-aside, competitively awarded contract with performance at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a $3,449.50 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on September 12, 2025, with completion scheduled for September 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger federal contract vehicle. The order will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $14,091.29 firm fixed-price delivery order to Amerisourcebergen Drug Corp (parent company Cencora, Inc.) on January 7, 2026, for TYPHIM VI 25 MCG/0.5 ML syringes. The contract is a non-set-aside award with an ultimate completion date of January 8, 2026 and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop Support Medical,...
- SPE2DR25D3111Indefinite Delivery Contract
- SPE2DR25D3111-SPE2DR26FF3WTDelivery Order
The Defense Logistics Agency awarded a $3,576.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringe vaccine product on January 13, 2026, with completion targeted for January 14, 2026. This is an unrestricted, competitively awarded contract with performance in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor and critical federal vendor specializing in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive portfolio of federal contract awards with DLA and other agencies demonstrates its capability to efficiently fulfill government requirements for essential pharmaceutical and medical commodities needed by military treatment facilities, veterans' healthcare programs, and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 1/12/26 |